LEO1

Across TCGA pan-cancer cohorts, LEO1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LEO1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LEO1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LEO1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where LEO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.969	0.773	.019	4	view →
LSCC	OS	Median	II,III,IV	0.908	0.637	.023	3	view →
CCRCC	DFS	Median	III,IV	0.582	0.818	.034	2	view →
HNSC	DFS	Quartile	All	1.000	0.924	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LEO1–LUAD (OS)

Open the LUAD breakdown →